COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Master Protocol for the phase 1 Study of Cell therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, including Long-term Safety Follow-up

Protocol No
ARCELLX-ACLX-001-DDBCMA
Principal Investigator
Binod Dhakal
Phase
I
Summary
This project is being done to study the effects of treatment with SPRX001 protein and ARC-T cells for the treatment of relapsed/refractory multiple myeloma.
Description
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL